Hormonal
Caloric restriction extends lifespan and delays age-related decline by activating SIRT1, which deacetylates and activates eNOS to improve vascular function and reduce oxidative stress.
To leverage this mechanism, consider implementing caloric restriction (e.g., reducing intake by 10-20% without malnutrition) to potentially activate SIRT1. This may improve vascular function and reduce oxidative stress, contributing to healthier aging. Consult a healthcare provider before making significant dietary changes.
Sirtuins are the epigenetic beneficial effectors of caloric restriction... SIRT1 deacetylases eNOS on Lys496 and Lys506 and stimulates its activity... SIRT1-eNOS coupling not only improves endothelium-dependent vasomotor tone... but possibly that of a larger number of cell types
Why this rating
The paper is a review summarizing multiple studies, including animal models and some human clinical data, but lacks large-scale randomized controlled trials for direct human application.
Source
Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases
Chiara Cencioni et al. · International Journal of Molecular Sciences · 2013
DOI 10.3390/ijms140917643
More from this paper
- Oxidative stress contributes to aging and age-related diseases by altering epigenetic markers, including DNA methylation and histone modifications, leading to cellular senescence and organ dysfunction.Good
- Resveratrol supplementation mimics the effects of caloric restriction by activating SIRT1, leading to metabolic and vascular benefits in obese humans.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →